Wednesday


Pharma Webinars

Oct. 27th

1

10AM – 11AM ET

Will the success of novel, gene-based therapies in advancing survival timelines in blood and bone marrow cancers be repeated in the solid tumor setting, with therapies that address each tumor’s individual genetic profile rather than association with its geographic location in the body?

Category: Hematologic Cancers and Gene-based “Tumor Agnostic” Therapies

Chair:
Stay tuned

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING


Dr_Ramon_Tiu_Astellas_Pharma_Web_3

Ramon V. Tiu, M.D.
Executive Medical Director, Astellas Pharma Global Development

Global Medical Leader, Gilteritinib Program
Astellas Pharma Inc.

 

> More about the product

Shefali Agarwal, MD, MPH, MBA
Chief Medical and Development Officer and trained medical oncologist

Epizyme

 

> More about the product

Dr. Michael G. Kauffman

Dr. Michael G. Kauffman, M.D., PhD
Chief Executive Officer and Co-Founder
Karyopharm Therapeutics Inc.

 

> More about the product

Mark Mogul
Head of Medical Affairs

Servier Pharmaceuticals

 

> More about the product

Dr. Iain Webb
Head of US Medical Affairs
Bayer Oncology

 

> More about the product


2

11AM – 12PM ET

What is the state of progress in building new therapeutic and diagnostic platforms to fight major cancers and address their prevalence in vulnerable populations, including the aged, minorities, and pediatric patients?

Category: Solid Tumor Cancers – |

Chair:
Jeffrey A Spaeder, M.D.

Chief Medical & Scientific Officer, and Senior Vice President
IQVIA

WHO IS SPEAKING


Ute Simon_200p

Dr. Ute Simon
Head Global Medical Affairs

Advanced Accelerator Applications Inc.

 

> More about the product

Steve L. Hoerter
President and Chief Executive Officer
Deciphera Pharmaceuticals

 

> More about the product


3

12PM – 1PM ET

What is the state of progress in building new therapeutic and diagnostic platforms to fight major cancers and address their prevalence in vulnerable populations, including the aged, minorities, and pediatric patients?

Category: Solid Tumor Cancers -||

Chair:
Stay tuned

WHO IS SPEAKING


Ted_Johnson_Pfizer_Pharma_Web2Ted_Johnson_Pfizer_Pharma_Web2

Ted W. Johnson, PhD
Research Fellow
Medicinal Chemistry, Pfizer Oncology
Pfizer Inc

 

> More about the product

Mimi_Huizinga_Novartis_Pharma_Web_2_3

Mimi Huizinga, M.D.
Vice President and Head, US Oncology Medical

Novartis Pharmaceuticals

 

> More about the product

Adam Schayowitz, PhD, MBA
Medicine Team Group Lead (Breast Cancer, Colorectal Cancer and Melanoma)

Pfizer Oncology

 

> More about the product

Juan Camilo Arjona Ferreira, MD
Chief Medical Officer, Myovant Sciences Ltd., Myovant Sciences, Inc.
Myovant Sciences GmbH

 

> More about the product

Peter Langmuir, M.D.
Group Vice President of Oncology Targeted Therapeutics
Incyte

 

> More about the product


4

1PM – 2PM ET

Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these high-cost, high-touch treatments?

Category: Rare Diseases

Chair:
Sanskriti Thakur
Special Advisor to CEO
Medable

WHO IS SPEAKING


JoAnne Micale Foody, MD, FACC, FAHA
Chief Medical Officer
Esperion

 

> More about the product

Savita Nandal
VP and Medical Head of Hematology Medical Franchise

Novartis Pharmaceuticals

 

> More about the product

Colin Hislop, MBBS
Senior Vice President of Clinical & Development Operations

Eiger Biopharmaceuticals Inc.

 

> More about the product


5

2PM – 3PM ET

What can patients with chronic conditions expect from medicines advances within the next five to ten years? How is chronic disease research moving from incremental and maintenance therapies to real breakthroughs toward cure and prevention?

Category: Chronic Diseases

Chair:
Boris Bogdan
Global Lead Medical

Accenture

WHO IS SPEAKING


Dr. Steph de Bono MD PhD
Senior Medical Director

Eli Lilly and Company

 

> More about the product

David_Platt_Novartis_Pharma_Web_1

David Platt, M.D.
Vice President, Medical Unit Head

Cardiovascular, Renal & Metabolism Medical Unit  
Novartis Pharmaceuticals Corporation

 

> More about the product

Eric_Pearlman_Eli_Lilly__BioTech_Web_1_Pharna_Web_1

Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs

Eli Lilly and Company

 

> More about the product

Vlad Coric, MD,
CEO
Biohaven Pharmaceuticals

 

> More about the product

Pradip Kumar Sasmal, PhD
Vice President and Head of CMC, Differentiated Products
Dr. Reddy’s Laboratories

 

> More about the product


6

3PM – 4PM ET

With a global pandemic raising awareness of the importance of vaccines and anti-viral/anti-microbial drugs, are private-sector R&D incentives aligned to meet these unmet medical needs?

Category: Infectious Diseases and Reproductive Therapy

Chair:
William Looney

Executive Advisory Board Member
The Galien Foundation

WHO IS SPEAKING


Mark Sullivan
Founder and Managing Director
Medicines Development for Global Health

 

> More about the product

Anu Osinusi
Vice President, Clinical Research for Hepatitis, Respiratory and Emerging Viruses

Gilead Sciences

 

> More about the product

Dennis_Hruby_Siga_Pharma_Web_4

Dennis E. Hruby, PhD
Chief Scientific Officer
SIGA Technologies, Inc.

 

> More about the product